Cite
The efficacy of abatacept in reducing synovial T cell activation by CD1c myeloid dendritic cells is overruled by the stimulatory effects of T cell-activating cytokines.
MLA
Moret, F. M., et al. “The Efficacy of Abatacept in Reducing Synovial T Cell Activation by CD1c Myeloid Dendritic Cells Is Overruled by the Stimulatory Effects of T Cell-Activating Cytokines.” Arthritis & Rheumatology (Hoboken, N.J.), vol. 67, no. 3, Mar. 2015, pp. 637–44. EBSCOhost, https://doi.org/10.1002/art.38982.
APA
Moret, F. M., Bijlsma, J. W. J., Lafeber, F. P. J. G., & van Roon, J. A. G. (2015). The efficacy of abatacept in reducing synovial T cell activation by CD1c myeloid dendritic cells is overruled by the stimulatory effects of T cell-activating cytokines. Arthritis & Rheumatology (Hoboken, N.J.), 67(3), 637–644. https://doi.org/10.1002/art.38982
Chicago
Moret, F M, J W J Bijlsma, F P J G Lafeber, and J A G van Roon. 2015. “The Efficacy of Abatacept in Reducing Synovial T Cell Activation by CD1c Myeloid Dendritic Cells Is Overruled by the Stimulatory Effects of T Cell-Activating Cytokines.” Arthritis & Rheumatology (Hoboken, N.J.) 67 (3): 637–44. doi:10.1002/art.38982.